The Conversation (0)
Theralase Technologies announced it received a second US patent for their lead anti-cancer compound technology.
Theralase Technologies (TSXV:TLT; OTCQX:TLTFF) announced it received a second US patent for their lead anti-cancer compound technology.
As quoted in the press release:
The patent deals with the composition of tunable metal-based thiophene PDCs used as therapeutic agents and as in-vivo diagnostic agents for treating or preventing diseases that involve hyperproliferating cell etiology, including: cancer and diseases associated with hyperproliferating cells. The compositions are also useful for treating infectious diseases and for pathogen disinfection.
Roger Dumoulin-White, President and CEO of Theralase stated that, “Theralase continues to build its patent portfolio for its anti-cancer division, providing protection from competition as the Company advances towards commercialization of this technology through the clinical study process. The Company is actively involved in the second phase of a Phase Ib clinical trial for Non-Muscle Invasive Bladder Cancer (“NMIBC“) focused on enrolling and treating the next six patients at the therapeutic dose of its lead PDC, TLD-1433 (0.70 mg/cm2).”
Click here to read the full press release.
Source: www.accesswire.com